[go: up one dir, main page]

MXPA06013221A - Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonistas enantiomericamente puros. - Google Patents

Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonistas enantiomericamente puros.

Info

Publication number
MXPA06013221A
MXPA06013221A MXPA06013221A MXPA06013221A MXPA06013221A MX PA06013221 A MXPA06013221 A MX PA06013221A MX PA06013221 A MXPA06013221 A MX PA06013221A MX PA06013221 A MXPA06013221 A MX PA06013221A MX PA06013221 A MXPA06013221 A MX PA06013221A
Authority
MX
Mexico
Prior art keywords
agonists
enantiomerically pure
formulations containing
powder formulations
inhalation powder
Prior art date
Application number
MXPA06013221A
Other languages
English (en)
Inventor
Michael Trunk
Joerg Schiewe
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35058202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA06013221(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MXPA06013221A publication Critical patent/MXPA06013221A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere a formulaciones en polvo para la inhalacion que contienen beta-agonistas enantiomericamente puros de la formula general (1) (ver formula (1)) en donde los radicales R1, R2, R3 y R4 se definen como en las reivindicaciones y descripciones y estan opcionalmente incorporados en especial de sus sales por adicion de acidos farmaceuticamente tolerables, asi como eventualmente en combinacion con un coadyuvante farmaceuticamente tolerable. Se describe tambien un procedimiento para su preparacion y a su uso como medicamentos, en especial como medicamentos para el tratamiento de enfermedades de las vias respiratorias.
MXPA06013221A 2004-05-14 2005-05-11 Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonistas enantiomericamente puros. MXPA06013221A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004024451A DE102004024451A1 (de) 2004-05-14 2004-05-14 Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
PCT/EP2005/005078 WO2005110359A1 (de) 2004-05-14 2005-05-11 Pulverformulierungen für die inhalation, die enantiomerenreine betaagonisten enthalten

Publications (1)

Publication Number Publication Date
MXPA06013221A true MXPA06013221A (es) 2007-02-08

Family

ID=35058202

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06013221A MXPA06013221A (es) 2004-05-14 2005-05-11 Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonistas enantiomericamente puros.

Country Status (24)

Country Link
EP (1) EP1809236B1 (es)
JP (1) JP4891899B2 (es)
KR (1) KR101270449B1 (es)
CN (1) CN1984638A (es)
AR (1) AR048899A1 (es)
AU (1) AU2005244424B2 (es)
BR (1) BRPI0511136A (es)
CA (1) CA2565915C (es)
DE (1) DE102004024451A1 (es)
DK (1) DK1809236T3 (es)
EA (1) EA012582B1 (es)
ES (1) ES2401786T3 (es)
IL (1) IL179215A (es)
MX (1) MXPA06013221A (es)
MY (1) MY145838A (es)
NO (1) NO20065078L (es)
PE (1) PE20060239A1 (es)
PL (1) PL1809236T3 (es)
SG (1) SG152258A1 (es)
TW (1) TW200607508A (es)
UA (1) UA86807C2 (es)
UY (1) UY28896A1 (es)
WO (1) WO2005110359A1 (es)
ZA (1) ZA200607785B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
BRPI0614410A2 (pt) 2005-08-15 2011-03-29 Boehringer Ingelheim Int processo para preparação de betamiméticos
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
JP5555255B2 (ja) 2008-12-30 2014-07-23 プルマゲン セラピューティクス（インフラメーション）リミテッド 呼吸器疾患の治療のためのスルホンアミド化合物
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
EP2906218B1 (en) 2012-10-09 2016-12-14 Boehringer Ingelheim International GmbH Beta-2-adrenoceptor agonist for the treatment of cough
US20200069679A1 (en) 2016-12-12 2020-03-05 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
EP1305300A1 (de) * 2000-04-27 2003-05-02 Boehringer Ingelheim Pharma GmbH & Co.KG Neue, langwirksame betamimetika, verfahren zu deren herstellung und deren verwendung als arzneimittel
GB0107106D0 (en) * 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
DE10141377A1 (de) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
UA80123C2 (en) 2002-04-09 2007-08-27 Boehringer Ingelheim Pharma Inhalation kit comprising inhalable powder of tiotropium
DE10253282A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung

Also Published As

Publication number Publication date
EA012582B1 (ru) 2009-10-30
CA2565915C (en) 2013-12-10
CA2565915A1 (en) 2005-11-24
MY145838A (en) 2012-04-30
BRPI0511136A (pt) 2007-11-27
IL179215A0 (en) 2007-03-08
EP1809236A1 (de) 2007-07-25
KR20070016169A (ko) 2007-02-07
JP2007537195A (ja) 2007-12-20
PL1809236T3 (pl) 2013-05-31
UA86807C2 (ru) 2009-05-25
IL179215A (en) 2011-04-28
UY28896A1 (es) 2005-12-30
PE20060239A1 (es) 2006-03-27
CN1984638A (zh) 2007-06-20
DK1809236T3 (da) 2013-02-11
ZA200607785B (en) 2008-07-30
AU2005244424B2 (en) 2010-12-23
AR048899A1 (es) 2006-06-07
EA200602016A1 (ru) 2007-06-29
DE102004024451A1 (de) 2005-12-22
JP4891899B2 (ja) 2012-03-07
KR101270449B1 (ko) 2013-06-04
TW200607508A (en) 2006-03-01
EP1809236B1 (de) 2012-12-26
ES2401786T3 (es) 2013-04-24
AU2005244424A1 (en) 2005-11-24
WO2005110359A1 (de) 2005-11-24
SG152258A1 (en) 2009-05-29
NO20065078L (no) 2006-11-28

Similar Documents

Publication Publication Date Title
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
MXPA06013221A (es) Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonistas enantiomericamente puros.
WO2007138472A3 (en) Triazolopyridazine derivatives
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
WO2004037807A3 (en) Medicinal arylethanolamine compounds
TW200738242A (en) Dihydropteridinones in the treatment of respiratory diseases
TW200508180A (en) Therapeutic agents
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
SG148177A1 (en) Novel cis-imidazolines
EP2039686A4 (en) DIHYDROPYRIMIDIN COMPOUNDS AND THEIR USES IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT AND PREVENTION OF ANTIVIRAL DISEASES
WO2008000483A3 (en) Phenol derivatives for the treatment of respiratory diseases
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
UA85707C2 (ru) Бензоксазины для лечения заболеваний дыхательных путей
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2005111002A3 (de) Substituierte cycloalkylderivate zur behandlung von atemswegerkrankungen
UY27757A1 (es) Medicamento que contiene betamiméticos y un nuevo anticolinérgico.
WO2003087049A3 (de) Arzneimittelkombinationen enthaltend heterocyclische verbindungen und ein neues anticholinergikum
MX2007004740A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica.
MXPA05013628A (es) Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3.
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
MXPA05005790A (es) Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central.
NO20054767L (no) Sammensetninger omfattende apomorfin for inhalering i lunge

Legal Events

Date Code Title Description
FG Grant or registration